Case reports in oncology · 2026
Primary Salivary Clear Cell Carcinoma with Response to Checkpoint Inhibition: Case Report and Review of the Literature.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schaeffer Samuel F, Mirsky Matthew M
Аннотация
INTRODUCTION: Primary salivary clear cell carcinoma (CCC) is a rare tumor of the minor salivary glands that is often seen as low-grade and responsive to resection. Limited data exist for its response to systemic chemotherapy or immune therapy.
CASE PRESENTATION: A 76-year-old male presented with recurrent, widely metastatic salivary CCC over 3 years after local resection with bilateral selective neck dissections. Advanced imaging showed biopsy-confirmed metastasis to the omentum, lungs, pleural effusion, and lymph nodes. Stable disease was achieved with carboplatin/paclitaxel therapy, but treatment was not tolerated by the patient due to side effects. Patient has been treated with single-agent pembrolizumab for 12 cycles with continued disease control and improvement in effusion.
CONCLUSION: Despite the low immunogenicity of this tumor, a clinically positive response was achieved with PD-(L)1 inhibition. More research is needed to identify systemic targeted therapies for CCC and tumors with low immunogenicity.
CASE PRESENTATION: A 76-year-old male presented with recurrent, widely metastatic salivary CCC over 3 years after local resection with bilateral selective neck dissections. Advanced imaging showed biopsy-confirmed metastasis to the omentum, lungs, pleural effusion, and lymph nodes. Stable disease was achieved with carboplatin/paclitaxel therapy, but treatment was not tolerated by the patient due to side effects. Patient has been treated with single-agent pembrolizumab for 12 cycles with continued disease control and improvement in effusion.
CONCLUSION: Despite the low immunogenicity of this tumor, a clinically positive response was achieved with PD-(L)1 inhibition. More research is needed to identify systemic targeted therapies for CCC and tumors with low immunogenicity.